Basket | Login


Alpha Cognition receives FDA approval to proceed with the clinical development of Alpha-1062 for AD

Tuesday 07 September 2021

On 7 September, Alpha Cognition, a biopharmaceutical company committed to developing novel therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and amyotrophic lateral sclerosis, announced that the US Food and Drug Administration (FDA) has accepted its investigational new drug application for its lead candidate, Alpha-1062, to proceed with the pivotal clinical phase of the development program for mild to moderate AD. The company plans to start enrollment in Q3 2021. Alpha-1062 is being developed as a new generation of acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer’s type.